Liraglutide, in plain words
What does it do?
Liraglutide acts like a gut hormone that helps the body manage appetite and blood sugar.
The official medicine information for liraglutide (Saxenda) describes it as a daily shot.
Does the brand tell me what it is for?
As of September 2026, liraglutide (Victoza) has U.S. approval for type 2 diabetes, a condition that affects blood sugar.
As of September 2026, liraglutide (Saxenda) is approved in the U.S. for long-term weight care in certain people.
For adults, this covers obesity, meaning excess body weight, or being overweight with a weight-related health problem.
Ask the clinician which description, if either, fits you and how they checked.
Ask which kind of product it is
Is it an approved generic?
FDA means the U.S. Food and Drug Administration.
The word generic identifies an approved medicine that copies a brand product.
Both uses have FDA-approved generics: liraglutide for diabetes and liraglutide for weight care, as of September 2026.
A pharmacist cannot treat a diabetes-use version as a direct replacement for a weight-use version, or the other way round.
Is it compounded instead?
Compounding makes a medicine to fill an order, unlike supplying a ready-made product that has approval.
Compounded products lack FDA approval; that is their status as of September 2026. There is no agency review before sale of how well they work, what harms they pose or their quality.
Ask about supply before you start
Could the medicine become hard to get?
In the September 2026 FDA record, liraglutide injection remains on the national shortage list.
The maker says its last Saxenda shipments to companies that supply pharmacies will be in late January 2027.
It says this decision is not due to a safety or quality problem.
Ask which exact product would be supplied and what the plan is if it becomes hard to get.
What could change for made-to-order medicine?
Some larger facilities prepare batches of medicine, frequently supplying hospitals and clinics.
As of September 2026, FDA has proposed leaving liraglutide off a list of raw ingredients these facilities may use to make medicine.
It has not made a final decision on that proposal.